Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $5000.0.

  • Lineage Cell Therapeutics' Cost of Revenue fell 8684.21% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $234000.0, marking a year-over-year decrease of 4633.03%. This contributed to the annual value of $334000.0 for FY2024, which is 5022.35% down from last year.
  • Lineage Cell Therapeutics' Cost of Revenue amounted to $5000.0 in Q3 2025, which was down 8684.21% from $39000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Cost of Revenue registered a high of $985000.0 during Q3 2021, and its lowest value of -$455000.0 during Q4 2022.
  • In the last 5 years, Lineage Cell Therapeutics' Cost of Revenue had a median value of $125000.0 in 2021 and averaged $150157.9.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 86568.63% in 2021, then crashed by 32303.92% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Cost of Revenue (Quarter) stood at $204000.0 in 2021, then tumbled by 323.04% to -$455000.0 in 2022, then soared by 156.26% to $256000.0 in 2023, then tumbled by 39.84% to $154000.0 in 2024, then crashed by 96.75% to $5000.0 in 2025.
  • Its Cost of Revenue stands at $5000.0 for Q3 2025, versus $39000.0 for Q2 2025 and $36000.0 for Q1 2025.